In this special report, The Daily Transcript profiles some of the leading CEOs turning local biotech companies into regional success stories. We'll also provide the latest news on the life sciences industry around the world.

  • Southwest California is becoming biotech incubator

    Just one-hour north of San Diego is Southwest California, a fast growing region that has become a fertile incubator of biotech and medical device companies.

  • BioMed Realty Trust acquires properties in San Diego

    BioMed Realty Trust, Inc. (NYSE: BMR) announced Tuesday it has acquired additional properties in San Diego, New Jersey and the San Francisco Bay Area worth a total value of $29.2 million.

  • We are in the business of building

    Good & Roberts Inc., a Vista-based general contractor, is celebrating 26 years of building San Diego -- building relationships, building a long list of repeat clients and building a reputation of honesty, integrity and quality within the commercial building industry.

  • Juanita Brooks, Principal

    Biotech IP Litigator

  • Biotech leaders assemble in Sacramento for annual life sciences day

    California biotechnology industry representatives converged in Sacramento recently for the industry's annual California Life Sciences Day.

  • San Diego poised to fill gaps in Big Pharma's R&D pipeline

    In recent years, Big Pharma's research drug development pipeline has been emptying more rapidly than it is being filled. As Big Pharma looks increasingly toward small biotech companies to correct the deficit, San Diego's life sciences community will continue to be at the forefront of innovation to help meet the demand for new biotech discoveries.

  • Pharmaceutical research tool patents: value hanging in the balance

    On April 20, the Supreme Court will hear an appeal related to the enforcement of pharmaceutical research tool patents. The court will ultimately decide whether a party can make or use inventions embraced by such patents without permission from the patent holder. Its decision will substantially affect the value of any portfolio directed to such inventions.

  • Before going global, protect your IP

    Pick up a current business or trade publication and chances are you'll find at least one article dedicated to global outsourcing. Global outsourcing has been heralded by industry leaders as the latest and greatest way to cut costs, leverage your resources and gain competitive advantage. While the financial market was quick to jump into global outsourcing, the biotech and pharmaceutical industry has been slowly testing the waters.

  • Salk Institute celebrates anniversary of polio vaccine

    On the morning of April 12, hundreds of Salk Institute for Biological Studies scientists, graduate students and staff will begin their day at the institute by celebrating the 50th anniversary of the vaccine that has saved them -- and millions of others -- from becoming crippled or dying from poliomyelitis or polio.

  • Deisseroth continues crusade to develop cancer vaccine

    On Christmas day in 2000, Dr. Albert B. Deisseroth got an unexpected but very welcomed gift. Going into the lab to check on a group of mice that a month earlier had been inoculated with an experimental cancer vaccine, he and his assistant discovered the mice showed no signs of cancer. They were elated. But a greater treat was yet to come.

  • Vijay B. Samant


  • Thomas L. Cantor


  • Stanley T. Crooke, M.D., Ph.D.


  • Gregory T. Lucier


  • Kim D. Blickenstaff


  • Jack Lief


  • Ginger L. Graham


  • Ligand's Targretin fails lung cancer trials

    While it works for lymphoma, Ligand Pharmaceutical's drug Targretin has failed as a primary treatment for lung cancer.

  • Panel: Stem cell research promising for patients, risky for capitalists

    While California's $3 billion stem cell research push has been getting a lot of attention, questions still linger regarding when and how taxpayers and the biotech industry will benefit from the research.

  • Monsanto on a tear with global biotech victories

    ST. LOUIS -- When Monsanto Co. (NYSE: MON) scrapped its plans last May to market its most-anticipated product in years -- genetically modified wheat -- even biotechnology's most ardent supporters complained about the company's lackluster pipeline.

  • Scripps board votes to stick with original site for biotech park

    WEST PALM BEACH, Fla. -- The Scripps Research Institute rejected an alternate Palm Beach County site to build its biotechnology park, instead choosing to support the selection of a rural citrus grove for the $800 million taxpayer-funded project.

  • Ambit Biosciences expands drug discovery, development teams

    Ambit Biosciences announced Thursday the appointments of Robert deGroof, Ph.D., to the position of senior vice president of Development and Shripad Bhagwat, Ph.D., to the position of senior vice president of Drug Discovery.

  • New interim president formally hired for stem cell institute

    The new interim president of California's $3 billion stem cell research institute said his first task will be to "raid everyplace I can" to hire top scientific talent.

  • Industry reacts to Biogen Idec drug recall

    Members of the local biotech community had mixed feelings Tuesday as to the potential fallout from Biogen Idec Inc. and Elan Corp's withdrawal of their highly anticipated new multiple sclerosis drug, Tysabri.

  • Genetronics initiates pancreatic cancer clinical trial

    Genetronics Biomedical Corp. (AMEX: GEB), a late-stage developer of oncology and other therapies using electroporation to deliver drugs and nucleic acids, announced Tuesday that it has initiated a Phase I clinical trial to treat pancreatic cancer using its MedPulser Tumor Ablation System.

  • Pfizer buys Idun Pharmaceuticals

    Pfizer Inc., the world's largest drug company, agreed to buy local biotech Idun Pharmaceuticals on Thursday, in a move signaling the pharmaceutical giant's continued expansion in San Diego.

  • Pharmaceutical companies face new laws on marketing and use of medical information

    Two new laws enacted by the California Legislature regulate the marketing practices of pharmaceutical companies (Senate Bill 1765), and impose new requirements on companies that collect medical information in the course of marketing activities (Senate Bill 1633).

National News

  • Monsanto on a tear with global biotech victories

    ST. LOUIS -- When Monsanto Co. (NYSE: MON) scrapped its plans last May to market its most-anticipated product in years -- genetically modified wheat -- even biotechnology's most ardent supporters complained about the company's lackluster pipeline.